What do we know and what don't we know about tamoxifen in the human uterus
- 1 January 1994
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 31 (1) , 27-39
- https://doi.org/10.1007/bf00689674
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Antiestrogen Resistance: Mechanisms by Which Breast Cancer Cells Undermine the Effectiveness of Endocrine TherapyJNCI Journal of the National Cancer Institute, 1991
- Endometrial lesions in patients undergoing tamoxifen therapyInternational Journal of Gynecology & Obstetrics, 1991
- Tamoxifen and Partial Oestrogen Agonism in Postmenopausal WomenAge and Ageing, 1991
- Endometrial side effects with tamoxifen for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- ADJUVANT TAMOXIFEN AND SECOND CANCERSThe Lancet, 1989
- Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifenJournal of Steroid Biochemistry, 1988
- Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol redThe Journal of Steroid Biochemistry and Molecular Biology, 1988
- Severe lipemia induced by tamoxifenCancer, 1986
- Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesteraseBiochemical and Biophysical Research Communications, 1984
- Estrogen-Like Action of Tamoxifen on Vaginal Epithelium in Breast Cancer PatientsOncology, 1981